158 Chapter 5 20. AJCC. Cancer staging 7th edition. 21. Boccaccio C, Gaudino G, Gambarotta G, Galimi F, Comoglio PM. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem 1994;269:12846-51. 22. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42. 23. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300. 24. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83. 25. Ding D, Stokes W, Eguchi M, Hararah M, Sumner W, Amini A, et al. Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. JAMA Otolaryngol Head Neck Surg 2019;145:53-61. 26. Mermod M, Tolstonog G, Simon C, Monnier Y. Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol 2016;62:60-71. 27. Saggi S, Badran KW, Han AY, Kuan EC, St John MA. Clinicopathologic Characteristics and Survival Outcomes in Floor of Mouth Squamous Cell Carcinoma: A Population-Based Study. Otolaryngol Head Neck Surg 2018;159:51-8. 28. Xu Q, Wang C, Li B, Kim K, Li J, Mao M, et al. The impact of age on oral squamous cell carcinoma: A longitudinal cohort study of 2,782 patients. Oral Dis 2019;25:730-41. 29. Zhao Z, Ge J, Sun Y, Tian L, Lu J, Liu M, et al. Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and meta-analysis. Oral Oncol 2012;48:761-7. 30. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016;40:244-52. 31. Dako. HercepTestTM Interpretation Manual - Breast Cancer. https://www.agilent.com/cs/library/usermanuals/ public/28630_herceptest_interpretation_manual-breast_ihc_row.pdf. Accessed: 26 February 2020. 32. Roche. Guiding immunotherapy decisions. https://diagnostics.roche.com/nl/en/products/tests/ventana-pd-l1-_ sp263-assay1.html. Accessed: 26 February 2020. 33. Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci 2009;100:633-8. 34. Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer 2018;18:341-58. 35. Koch JP, Aebersold DM, Zimmer Y, Medova M. MET targeting: time for a rematch. Oncogene 2020;39:2845-62.
RkJQdWJsaXNoZXIy MTk4NDMw